12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral treprostinil: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III FREEDOM-C2 trial in 270 evaluable patients with PAH currently receiving background therapy with an endothelin receptor antagonist and/or phosphodiesterase-5 (PDE-5) inhibitor showed that twice-daily oral treprostinil missed the primary endpoint of significantly improving median 6MWD from baseline to week 16 vs. placebo. Specifically, the placebo-corrected median change in 6MWD at week 16 was 10 meters (p=0.089). Additionally, oral treprostinil did not significantly improve the placebo-corrected median...

Read the full 356 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >